Brokerages Set Vigil Neuroscience, Inc. (NASDAQ:VIGL) Target Price at $10.80

Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) have been assigned a consensus rating of "Hold" from the ten research firms that are currently covering the stock, MarketBeat reports. Ten equities research analysts have rated the stock with a hold recommendation. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $10.80.

A number of analysts have issued reports on the stock. Citizens Jmp lowered shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 22nd. HC Wainwright lowered shares of Vigil Neuroscience from a "buy" rating to a "neutral" rating and cut their price target for the stock from $14.00 to $8.00 in a research note on Tuesday, May 27th. Citigroup lowered shares of Vigil Neuroscience to a "market perform" rating in a research note on Thursday, May 22nd. JMP Securities reiterated a "market perform" rating on shares of Vigil Neuroscience in a research note on Thursday, May 22nd. Finally, Stifel Nicolaus downgraded Vigil Neuroscience from a "buy" rating to a "hold" rating and cut their price target for the stock from $11.00 to $8.00 in a report on Wednesday, May 28th.

Vigil Neuroscience Stock Performance

Shares of NASDAQ:VIGL traded up $0.01 during trading on Friday, reaching $8.05. The stock had a trading volume of 315,246 shares, compared to its average volume of 684,684. The business has a fifty day moving average price of $6.51 and a 200-day moving average price of $3.60. The stock has a market cap of $383.90 million, a PE ratio of -3.93 and a beta of 3.34. Vigil Neuroscience has a 1-year low of $1.31 and a 1-year high of $8.06.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04. Sell-side analysts expect that Vigil Neuroscience will post -2.07 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in VIGL. Blair William & Co. IL purchased a new position in shares of Vigil Neuroscience in the 4th quarter valued at about $551,000. Renaissance Technologies LLC grew its stake in Vigil Neuroscience by 698.5% during the 4th quarter. Renaissance Technologies LLC now owns 367,300 shares of the company's stock worth $624,000 after buying an additional 321,300 shares during the last quarter. Barclays PLC grew its stake in Vigil Neuroscience by 43.6% during the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock worth $109,000 after buying an additional 19,436 shares during the last quarter. Marshall Wace LLP grew its stake in Vigil Neuroscience by 85.3% during the 4th quarter. Marshall Wace LLP now owns 266,895 shares of the company's stock worth $454,000 after buying an additional 122,853 shares during the last quarter. Finally, Boothbay Fund Management LLC purchased a new position in Vigil Neuroscience during the 4th quarter worth approximately $249,000. Hedge funds and other institutional investors own 83.64% of the company's stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.